- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: 9F3v13 | RhuMAB IFNalpha | rhuMAb interferon-α
Compound class: Antibody
Comment: Rontalizumab is a humanized monoclonal antibody targeting interferon alpha (IFNα) that has immunomodulatory potential. It was humanized from a mouse monoclonal as described in , and peptide sequences of the antibody (identified as humanized 9F3v13) are claimed in Genentech patent US7582445 .
Rontalizumab is functionally similar to sifalimumab. Development of both of these anti-IFNα agents has been discontinued. Compare these with anifrolumab, which targets the type I interferon receptor (IFNAR1) rather than the ligand itself, and which has progressed to Phase 3 clinical trial.
A 3D X-ray structure of rontalizumab's Fab domain bound to IFNα2 has been published (PDB identifier 4Z5R) .
|No information available.|
|Summary of Clinical Use|
|Clinical development was discontinued after a failure to show efficacy in a Phase 2 clinical trial (NCT00962832) in patients with systemic lupus erythematosus (SLE) .|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT00962832||A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus||Phase 2 Interventional||Genentech, Inc.|